A Phase 3 interventional study of dimethyl fumarate and Placebo in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 246 sites in 34 countries. Open to participants aged 19 Years to 58 Years. Per ClinicalTrials.gov, last updated 2020-12-31.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is one of 2 that started in 2009, is one of 10 in phase 3, and was the 3rd registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 19 Years to 58 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2009.
This study's enrollment of 1,736 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 2nd largest by enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2009, is one of 25 in phase 3, and was the 21st registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.
The initial BG00012 dosage for the extension study (240 mg BID or 240 mg TID) was the same as that used in the Phase 3 Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451). Subsequent to the initiation of this study, BG00012 was approved in several countries for the treatment of MS at a dose of 240 mg BID. For this reason, all participants continuing in this study will receive the currently marketed dose of 240 mg BID.
Key Inclusion Criteria:
-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
Drug: dimethyl fumarate · Drug: Placebo
In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
Drug: dimethyl fumarate
BG00012 capsules
Also known as: BG00012, Tecfidera, DMF
Capsules taken to maintain the blind in the 240 mg BID treatment group.
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Day 1 up to Week 561
Percentage of Participants Who Had Relapses
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.
Time frame: Day 1 up to Week 384
Annualized Relapse Rate (ARR)
The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.
Time frame: Day 1 up to Week 384
Change From Baseline in the Expanded Disability Status Scale (EDSS) at Week 384
EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.
Time frame: Baseline, Week 384
Number of Gadolinium (Gd)-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
The Gd-enhancing lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Volume of Gd-Enhancing Lesions as Measured by Magnetic Resonance Imaging (MRI)
The Gd-enhancing lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Number of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
The T2 lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Volume of New or Newly Enlarging T2 Lesions as Measured by Magnetic Resonance Imaging (MRI)
The T2 lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Number of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
The T1 hypointense lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Volume of T1 Hypointense Lesions as Measured by Magnetic Resonance Imaging (MRI)
The T1 hypointense lesions was evaluated using MRI technique.
Time frame: Baseline up to Week 288
Percent Change From Baseline in Brain Atrophy
Brain atrophy was measured using magnetic resonance imaging (MRI) technique.
Time frame: Baseline up to Week 288
Percent Change From Baseline in Magnetization Transfer Ratio (MTR)
Magnetization Transfer Ratio (MTR) was measured using MRI technique.
Time frame: Baseline up to Week 288
Change From Baseline in Short Form-36 Health Survey (SF-36®) at Week 384
The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.
Time frame: Baseline, Week 384
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - EQ-5D Index Score at Week 384
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) "no problems", (2) "some problems", or (3) "severe problems". A positive change from baseline indicates improvement.
Time frame: Baseline, Week 384
Change From Baseline in EuroQol 5 Dimensions Questionnaire (EQ-5D) Health Survey - Visual Analog Scale (VAS) at Week 384
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents "worst imaginable health state" and 100 represents "best imaginable health state". A positive change from baseline indicates improvement.
Time frame: Baseline, Week 384
Change From Baseline in Visual Function Test Scores at Week 384
Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.
Time frame: Baseline, Week 384
Participants were enrolled at 298 investigative sites from 03 February 2009 to 08 November 2019.
| Milestone | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|
| Started | 868 | 868 |
| Completed | 384 | 375 |
| Not completed | 484 | 493 |
| Withdrew: Ms relapse | 17 | 23 |
| Withdrew: Ms progression | 14 | 9 |
| Withdrew: Adverse event | 113 | 124 |
| Withdrew: Lost to follow-up | 22 | 19 |
| Withdrew: Consent withdrawn | 144 | 156 |
| Withdrew: Investigator decision | 42 | 42 |
| Withdrew: Participant non-compliance | 11 | 9 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Other | 115 | 104 |
| Withdrew: Other | 2 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
| Participants | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 824 | 814 |
Relapses were defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours.
| percentage of participants | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Had Relapses | 40 | 41 | 34 | 36 | 31 | 31 |
The annualized relapse rate is calculated as the total number of relapses occurred during the period for all participants, divided by the total number of participant-years followed in the period.
| relapses per participant-years | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Annualized Relapse Rate (ARR) | 0.159 | 0.179 | 0.200 | 0.199 | 0.184 | 0.212 |
EDSS scale ranges from 0 (Normal neurological exam, no disability) to 10 (Death) in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. Sustained disability progression was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS ≥1.0 that was sustained for at least 24 weeks, or a 1.5 point increase on the EDSS from a baseline EDSS =0 that was sustained for at least 24 weeks.
| score on a scale | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 2.44 ± 1.251 | 2.43 ± 1.144 | 2.50 ± 1.135 | 2.54 ± 1.218 | 2.57 ± 1.249 | 2.68 ± 1.231 |
| Change at Week 384 | 0.28 ± 1.160 | 0.26 ± 1.213 | 0.37 ± 1.328 | 0.53 ± 1.278 | 0.39 ± 1.217 | 0.49 ± 1.319 |
The Gd-enhancing lesions was evaluated using MRI technique.
| lesions | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Week 48 | 0.4 ± 1.87 | 0.4 ± 1.29 | 0.2 ± 0.66 | 0.3 ± 1.14 | 0.5 ± 1.19 | 0.4 ± 1.14 |
| Week 96 | 0.4 ± 1.77 | 0.4 ± 1.28 | 0.1 ± 0.38 | 0.2 ± 0.82 | 0.6 ± 1.33 | 0.3 ± 0.73 |
| Week 144 | 0.3 ± 1.66 | 0.4 ± 1.30 | 0.2 ± 0.44 | 0.1 ± 0.29 | 0.5 ± 2.48 | 0.3 ± 1.59 |
| Week 192 | 0.4 ± 2.02 | 0.5 ± 1.85 | 0.5 ± 1.72 | 0.3 ± 0.96 | 0.2 ± 0.60 | 0.6 ± 2.01 |
| Week 240 | 0.5 ± 3.14 | 0.5 ± 2.29 | 0.2 ± 0.50 | 0.2 ± 0.51 | 0.2 ± 0.58 | 0.3 ± 0.75 |
| Week 288 | 0.2 ± 0.74 | 0.5 ± 1.81 | 0.1 ± 0.40 | 0.7 ± 2.76 | 0.0 ± 0.00 | 0.3 ± 0.77 |
The Gd-enhancing lesions was evaluated using MRI technique.
| millimeter cube (mm^3) | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 31.7 ± 179.28 | 48.6 ± 205.43 | 96.0 ± 260.79 | 142.5 ± 459.76 | 37.1 ± 138.82 | 41.7 ± 116.55 |
| Week 48 | 59.6 ± 526.51 | 70.0 ± 366.63 | 18.8 ± 91.47 | 25.3 ± 108.19 | 42.5 ± 123.67 | 42.7 ± 148.11 |
| Week 96 | 49.1 ± 245.14 | 56.1 ± 271.29 | 27.7 ± 204.80 | 13.3 ± 67.01 | 64.3 ± 183.16 | 22.3 ± 60.83 |
| Week 144 | 44.1 ± 291.14 | 47.0 ± 169.68 | 18.8 ± 66.15 | 3.8 ± 25.03 | 42.6 ± 142.55 | 92.9 ± 397.69 |
| Week 192 | 39.1 ± 217.89 | 54.5 ± 251.31 | 45.8 ± 156.88 | 19.9 ± 79.19 | 12.0 ± 40.56 | 55.1 ± 169.16 |
| Week 240 | 96.8 ± 650.06 | 69.3 ± 374.67 | 21.7 ± 77.87 | 14.1 ± 45.22 | 17.5 ± 46.19 | 17.1 ± 48.41 |
| Week 288 | 18.2 ± 93.28 | 53.1 ± 250.87 | 7.9 ± 30.09 | 230.2 ± 1092.11 | 0.0 ± 0.00 | 34.1 ± 102.87 |
The T2 lesions was evaluated using MRI technique.
| lesions | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Week 48 | 1.6 ± 4.07 | 2.2 ± 6.15 | 2.7 ± 4.96 | 2.4 ± 5.45 | 3.4 ± 6.57 | 2.1 ± 3.83 |
| Week 96 | 3.4 ± 8.35 | 4.1 ± 10.01 | 3.8 ± 7.24 | 2.9 ± 6.78 | 4.9 ± 8.51 | 3.4 ± 5.13 |
| Week 144 | 4.2 ± 9.81 | 5.2 ± 10.01 | 4.0 ± 7.27 | 4.3 ± 10.12 | 5.7 ± 9.45 | 5.2 ± 9.68 |
| Week 192 | 5.8 ± 14.04 | 7.5 ± 15.14 | 5.6 ± 10.09 | 5.6 ± 14.19 | 5.5 ± 9.94 | 5.6 ± 13.35 |
| Week 240 | 7.4 ± 17.09 | 9.5 ± 20.33 | 8.2 ± 14.87 | 7.7 ± 17.89 | 6.8 ± 11.74 | 7.5 ± 16.76 |
| Week 288 | 8.2 ± 18.53 | 12.4 ± 28.23 | 7.5 ± 13.89 | 10.4 ± 22.05 | 8.9 ± 15.04 | 6.0 ± 8.90 |
The T2 lesions was evaluated using MRI technique.
| mm^3 | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 10231.9 ± 11214.17 | 10408.3 ± 12166.80 | 8883.7 ± 8570.10 | 10806.3 ± 12060.05 | 12628.9 ± 11258.69 | 13044.4 ± 14608.50 |
| Week 48 | 9951.9 ± 10750.15 | 9849.6 ± 10986.36 | 8992.1 ± 7952.13 | 10114.5 ± 10121.61 | 11160.7 ± 9565.55 | 12979.0 ± 14415.86 |
| Week 96 | 10331.3 ± 11359.81 | 10434.0 ± 12201.38 | 8645.2 ± 7787.60 | 9985.7 ± 10715.73 | 11318.1 ± 9873.73 | 13974.1 ± 15432.10 |
| Week 144 | 9930.1 ± 10686.26 | 10280.7 ± 11324.58 | 8829.4 ± 7482.93 | 9792.3 ± 9842.28 | 10188.5 ± 8064.09 | 12949.7 ± 14036.15 |
| Week 192 | 9837.7 ± 10845.04 | 10760.0 ± 11987.16 | 9077.6 ± 7794.52 | 10576.3 ± 12029.26 | 10421.9 ± 8773.41 | 11671.5 ± 13124.47 |
| Week 240 | 10611.2 ± 11633.95 | 11087.5 ± 12464.90 | 9711.1 ± 8709.46 | 10591.4 ± 11613.26 | 11009.9 ± 9551.94 | 12254.4 ± 13732.10 |
| Week 288 | 9611.8 ± 9447.18 | 9800.8 ± 11279.84 | 8819.8 ± 8866.90 | 10537.6 ± 10684.47 | 11586.3 ± 9728.19 | 10404.8 ± 12245.75 |
The T1 hypointense lesions was evaluated using MRI technique.
| lesions | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Week 48 | 0.8 ± 2.13 | 1.0 ± 2.37 | 1.8 ± 3.81 | 1.7 ± 3.71 | 2.0 ± 4.22 | 1.3 ± 2.64 |
| Week 96 | 1.7 ± 3.63 | 1.9 ± 3.91 | 1.8 ± 3.33 | 2.1 ± 5.00 | 3.0 ± 5.85 | 1.9 ± 3.44 |
| Week 144 | 2.0 ± 4.61 | 2.8 ± 5.19 | 2.0 ± 3.69 | 2.6 ± 7.02 | 3.1 ± 6.20 | 2.9 ± 5.19 |
| Week 192 | 2.9 ± 7.03 | 3.4 ± 6.79 | 2.9 ± 5.12 | 3.8 ± 10.71 | 3.3 ± 6.74 | 3.0 ± 7.14 |
| Week 240 | 3.4 ± 8.25 | 4.8 ± 9.39 | 4.0 ± 7.52 | 4.9 ± 13.30 | 4.0 ± 8.06 | 4.2 ± 10.20 |
| Week 288 | 2.7 ± 5.72 | 5.9 ± 12.02 | 4.5 ± 7.38 | 3.6 ± 4.51 | 1.0 ± 1.10 | 5.6 ± 6.81 |
The T1 hypointense lesions was evaluated using MRI technique.
| mm^3 | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 3640.1 ± 5598.31 | 3447.3 ± 4900.96 | 2754.2 ± 3552.30 | 3623.1 ± 5549.13 | 3204.3 ± 4221.55 | 3572.6 ± 4915.24 |
| Week 48 | 3829.5 ± 5824.26 | 3715.5 ± 5112.21 | 2891.9 ± 3034.00 | 3936.0 ± 5271.89 | 3271.0 ± 4157.24 | 3743.3 ± 5374.24 |
| Week 96 | 3841.2 ± 5682.74 | 3853.7 ± 5428.66 | 2921.0 ± 3327.93 | 3849.4 ± 5167.13 | 3510.4 ± 4672.80 | 3949.7 ± 5018.63 |
| Week 144 | 3767.4 ± 4969.23 | 4074.0 ± 5413.85 | 3145.6 ± 3366.27 | 4006.9 ± 5062.08 | 3499.2 ± 4198.50 | 4126.1 ± 5695.44 |
| Week 192 | 3834.9 ± 4942.19 | 4177.4 ± 5301.68 | 3385.4 ± 3575.44 | 4330.0 ± 5136.67 | 3592.0 ± 4069.39 | 4089.3 ± 4996.13 |
| Week 240 | 4038.6 ± 5145.85 | 4238.2 ± 5248.84 | 3406.4 ± 3936.73 | 3823.9 ± 4274.82 | 3503.4 ± 3933.75 | 4057.7 ± 5223.62 |
| Week 288 | 3603.3 ± 4394.60 | 3973.1 ± 5202.05 | 3350.6 ± 4140.34 | 4187.5 ± 4835.43 | 3264.9 ± 3639.91 | 2959.1 ± 3918.62 |
Brain atrophy was measured using magnetic resonance imaging (MRI) technique.
| percent change | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Change at Week 48 | -1.206 ± 1.1006 | -1.263 ± 1.0848 | -1.487 ± 1.3086 | -1.320 ± 1.4021 | -1.496 ± 1.1316 | -1.414 ± 1.1882 |
| Change at Week 96 | -1.372 ± 1.1382 | -1.500 ± 1.0893 | -1.589 ± 1.3630 | -1.775 ± 1.7191 | -1.883 ± 1.2383 | -1.810 ± 1.4556 |
| Change at Week 144 | -1.708 ± 1.4109 | -1.876 ± 1.2604 | -2.139 ± 1.5884 | -2.353 ± 1.7897 | -2.386 ± 1.3168 | -2.252 ± 2.2124 |
| Change at Week 192 | -2.138 ± 1.6831 | -2.117 ± 1.4000 | -2.230 ± 1.7755 | -2.476 ± 1.7062 | -2.645 ± 1.2284 | -2.417 ± 2.0486 |
| Change at Week 240 | -2.313 ± 1.6309 | -2.253 ± 1.3721 | -2.271 ± 1.4817 | -2.593 ± 1.9043 | -2.249 ± 1.2985 | -2.790 ± 2.2188 |
| Change at Week 288 | -2.216 ± 1.5744 | -2.271 ± 1.2193 | -2.470 ± 1.6757 | -2.849 ± 1.9648 | -2.657 ± 1.7051 | -2.496 ± 1.3699 |
Magnetization Transfer Ratio (MTR) was measured using MRI technique.
| percent change | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Change at Week 48 | -0.325 ± 5.4932 | -0.383 ± 4.8621 | 1.034 ± 7.3548 | -0.567 ± 4.4766 | -0.081 ± 13.6416 | -0.334 ± 1.5103 |
| Change at Week 96 | -0.427 ± 6.6493 | -0.532 ± 4.9880 | 1.630 ± 7.6584 | -0.947 ± 7.0771 | -4.269 ± 12.6065 | 0.215 ± 1.4270 |
| Change at Week 144 | -0.042 ± 9.2548 | 0.509 ± 7.2692 | 1.525 ± 8.6421 | 1.411 ± 12.2825 | -4.460 ± 10.3887 | 3.119 ± 8.1676 |
| Change at Week 192 | 1.038 ± 10.8680 | 0.955 ± 8.6105 | 3.012 ± 9.3831 | 3.103 ± 13.0046 | 1.384 ± 15.7611 | 3.841 ± 10.8600 |
| Change at Week 240 | -0.002 ± 15.6190 | 1.647 ± 8.3094 | 3.213 ± 9.6621 | 4.108 ± 13.8103 | 2.959 ± 16.8386 | 0.673 ± 25.9962 |
| Change at Week 288 | 0.002 ± 4.0206 | -0.391 ± 4.6415 | -0.666 ± 2.0741 | -0.622 ± 2.2922 | -0.466 ± 0.9410 | -1.114 ± 2.4539 |
The SF-36 is a brief (36-item) scale reflecting the impact of both dysfunctions and general health perception the questionnaire measures: 1.physical function (PF),2. role physical (RF),3. bodily pain (BP),4. role emotional (RE),5. social function (SF), 6. general health (GH),7. vitality (VT), 8. mental health (MH). Items 1-4 primarily contribute to the PCS score of the SF-36. Items 5-8 primarily contribute to the mental component summary (MCS) score of the SF-36. The questions related to each dimension are scored on a scale from 0 (worst score) to 100 (best score), with higher scores indicating better function.
| score on a scale | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline: Physical Functioning Score | 68.48 ± 25.938 | 71.78 ± 24.849 | 69.67 ± 24.481 | 67.97 ± 26.279 | 69.10 ± 25.226 | 68.20 ± 25.370 |
| Change at Week 384: Physical Functioning Score | 0.73 ± 21.972 | -4.79 ± 24.641 | -7.37 ± 22.253 | -6.89 ± 23.194 | -6.19 ± 21.719 | -6.25 ± 28.350 |
| Baseline: Role-Physical Score | 56.46 ± 41.254 | 58.42 ± 41.280 | 56.35 ± 40.896 | 59.87 ± 41.747 | 55.26 ± 40.390 | 53.57 ± 42.029 |
| Change at Week 384: Role-Physical Score | 3.20 ± 48.259 | -2.75 ± 47.283 | -10.00 ± 43.188 | -8.24 ± 53.177 | -12.21 ± 40.595 | -1.04 ± 54.568 |
| Baseline: Bodily-Pain Score | 69.68 ± 25.587 | 70.42 ± 24.688 | 68.51 ± 26.163 | 69.44 ± 26.016 | 69.30 ± 25.766 | 68.59 ± 26.102 |
| Change at Week 384: Bodily-Pain Score | 1.32 ± 28.525 | -1.47 ± 25.779 | -2.92 ± 23.486 | -4.36 ± 25.935 | -3.60 ± 22.138 | -4.46 ± 33.297 |
| Baseline: General Health Score | 53.99 ± 21.563 | 55.44 ± 20.768 | 54.45 ± 18.690 | 52.42 ± 20.028 | 51.21 ± 18.707 | 52.58 ± 19.675 |
| Change at Week 384: General Health Score | 0.87 ± 18.744 | -2.12 ± 20.595 | -2.28 ± 16.752 | -0.52 ± 22.035 | -5.64 ± 18.270 | 1.21 ± 21.674 |
| Baseline: Vitality Score | 50.48 ± 20.966 | 52.21 ± 19.842 | 50.63 ± 19.130 | 50.64 ± 21.069 | 51.30 ± 19.703 | 50.33 ± 20.019 |
| Change at Week 384: Vitality Score | 1.11 ± 19.857 | -0.73 ± 19.033 | -4.67 ± 17.934 | 0.40 ± 20.822 | -6.71 ± 20.236 | 1.03 ± 19.829 |
| Baseline: Social Functioning Score | 71.46 ± 24.451 | 71.53 ± 24.394 | 69.67 ± 24.581 | 72.23 ± 24.699 | 69.02 ± 24.688 | 69.53 ± 25.100 |
| Change at Week 384: Social Functioning Score | -2.16 ± 25.575 | -3.30 ± 24.912 | -5.69 ± 22.184 | -2.08 ± 27.724 | -10.76 ± 34.350 | -0.52 ± 25.780 |
| Baseline: Role-Emotional Score | 64.87 ± 40.653 | 65.57 ± 40.015 | 62.86 ± 42.715 | 62.61 ± 41.280 | 60.29 ± 41.393 | 64.26 ± 41.854 |
| Change at Week 384: Role-Emotional Score | 0.43 ± 49.950 | 0.47 ± 43.513 | -12.22 ± 42.532 | 4.17 ± 44.656 | -13.18 ± 42.501 | -3.55 ± 48.769 |
| Baseline: Mental Health Score | 65.01 ± 19.818 | 66.24 ± 19.060 | 65.42 ± 17.658 | 65.15 ± 19.233 | 62.30 ± 17.347 | 63.61 ± 18.414 |
| Change at Week 384: Mental Health Score | 1.32 ± 19.715 | 2.31 ± 18.095 | -3.91 ± 19.897 | 2.33 ± 17.524 | -0.29 ± 21.989 | -2.06 ± 20.066 |
| Baseline: Mental Component Score | 45.40 ± 11.130 | 45.63 ± 10.272 | 45.13 ± 10.932 | 45.31 ± 10.907 | 44.00 ± 10.702 | 45.03 ± 10.642 |
| Change at Week 384: Mental Component Score | 0.05 ± 12.415 | 0.87 ± 10.028 | -2.55 ± 10.328 | 1.97 ± 10.657 | -2.59 ± 12.895 | 0.08 ± 10.328 |
| Baseline: Physical Component Score | 43.53 ± 9.884 | 44.44 ± 10.048 | 43.74 ± 9.739 | 43.56 ± 10.267 | 43.68 ± 10.359 | 43.15 ± 10.091 |
| Change at Week 384: Physical Component Score | 0.55 ± 9.373 | -1.94 ± 10.532 | -2.29 ± 8.929 | -3.25 ± 9.998 | -2.70 ± 8.860 | -1.59 ± 10.765 |
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. The EQ-5D provides a profile of the participant's health state in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, the participant is instructed to indicate whether he or she has (1) "no problems", (2) "some problems", or (3) "severe problems". A positive change from baseline indicates improvement.
| score on a scale | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 0.73 ± 0.210 | 0.73 ± 0.222 | 0.72 ± 0.223 | 0.71 ± 0.244 | 0.71 ± 0.246 | 0.72 ± 0.189 |
| Change at Week 384 | 0.01 ± 0.251 | 0.00 ± 0.233 | -0.07 ± 0.269 | 0.00 ± 0.249 | -0.04 ± 0.253 | -0.03 ± 0.241 |
The EQ-5D is a generic health-related quality of life instrument consisting of 2 components, EQ-5D index score and EQ-VAS. In EQ-VAS participants are asked to rate their current health on a 20 centimeter (cm) scale from 0 to 100 where 0 represents "worst imaginable health state" and 100 represents "best imaginable health state". A positive change from baseline indicates improvement.
| score on a scale | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline | 70.97 ± 18.460 | 70.48 ± 19.993 | 70.40 ± 17.630 | 69.44 ± 19.907 | 66.80 ± 18.846 | 69.07 ± 20.094 |
| Change at Week 384 | -0.48 ± 19.631 | -1.67 ± 18.855 | -7.24 ± 18.419 | -3.17 ± 22.003 | -1.71 ± 25.330 | -4.11 ± 16.270 |
Participants were tested using the contrast level of 100%, 2.5%, and 1.25% charts, and the scores were defined as the number of letters identified correctly for each chart (the maximum score was 60). Higher scores indicate better functioning. A positive change from baseline indicates better functioning.
| score on a scale | BG00012 240 mg BID (Prior BG00012 240 mg BID) | BG00012 240 mg TID (Prior BG00012 240 mg TID) | BG00012 240 mg BID (Prior BG00012 Matched Placebo) | BG00012 240 mg TID (Prior BG00012 Matched Placebo) | BG00012 240 mg BID (Prior Glatiramer Acetate [GA]) | BG00012 240 mg TID (Prior Glatiramer Acetate [GA]) |
|---|---|---|---|---|---|---|
| Baseline: 100% Chart | 54.7 ± 7.95 | 55.0 ± 7.84 | 55.1 ± 7.26 | 54.8 ± 7.12 | 54.3 ± 8.26 | 55.0 ± 6.73 |
| Change at Week 384: 100% Chart | -0.4 ± 6.76 | -1.9 ± 6.81 | -1.4 ± 8.48 | -1.2 ± 7.53 | -1.6 ± 8.05 | -0.7 ± 5.17 |
| Baseline: 2.5% Chart | 32.4 ± 12.17 | 32.6 ± 11.76 | 32.4 ± 11.42 | 32.3 ± 11.99 | 31.8 ± 12.36 | 31.7 ± 12.41 |
| Change at Week 384: 2.5% Chart | -2.4 ± 10.77 | -3.3 ± 10.43 | -1.5 ± 11.77 | -4.9 ± 11.14 | -4.0 ± 11.90 | -2.1 ± 9.86 |
| Baseline: 1.25% Chart | 24.1 ± 12.45 | 24.2 ± 12.28 | 23.8 ± 12.11 | 23.7 ± 12.96 | 23.4 ± 11.76 | 22.2 ± 13.25 |
| Change at Week 384: 1.25% Chart | -5.8 ± 13.39 | -6.0 ± 11.77 | -4.1 ± 13.04 | -7.4 ± 12.42 | -6.7 ± 13.78 | -5.0 ± 12.74 |
Collected over From start of the study up to follow-up (up to Week 561). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BG00012 240 mg BID | 5/868 (0.6%) | 279/868 (32.1%) | 779/868 (89.7%) |
| BG00012 240 mg TID | 6/868 (0.7%) | 272/868 (31.3%) | 767/868 (88.4%) |
| Event | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 116/868 | 122/868 |
| FallInjury, poisoning and procedural complications | 13/868 | 18/868 |
| Urinary tract infectionInfections and infestations | 10/868 | 4/868 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/868 | 8/868 |
| CholelithiasisHepatobiliary disorders | 2/868 | 7/868 |
| PneumoniaInfections and infestations | 6/868 | 1/868 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/868 | 3/868 |
| Myocardial infarctionCardiac disorders | 1/868 | 5/868 |
| Road traffic accidentInjury, poisoning and procedural complications | 4/868 | 5/868 |
| Tibia fractureInjury, poisoning and procedural complications | 1/868 | 5/868 |
| Event | BG00012 240 mg BID | BG00012 240 mg TID |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 324/868 | 335/868 |
| NasopharyngitisInfections and infestations | 220/868 | 226/868 |
| Urinary tract infectionInfections and infestations | 196/868 | 164/868 |
| FlushingVascular disorders | 170/868 | 165/868 |
| HeadacheNervous system disorders | 145/868 | 131/868 |
| Upper respiratory tract infectionInfections and infestations | 143/868 | 136/868 |
| Back painMusculoskeletal and connective tissue disorders | 125/868 | 125/868 |
| DiarrhoeaGastrointestinal disorders | 111/868 | 118/868 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 97/868 | 115/868 |
| FatigueGeneral disorders | 100/868 | 102/868 |
Intent-to-Treat (ITT) population included participants who had entered study NCT00835770 and received at least one dose of study treatment. Data for ethnicity was not evaluated in the study.
| Age, Continuous(years) | BG00012 240 mg BID | BG00012 240 mg TID | Total |
|---|---|---|---|
| Mean | 39.6 ± 8.93 | 40.1 ± 9.23 | 39.8 ± 9.08 |
| Sex: Female, Male(Participants) | BG00012 240 mg BID | BG00012 240 mg TID | Total |
|---|---|---|---|
| Female | 616 | 596 | 1212 |
| Male | 252 | 272 | 524 |
| Race/Ethnicity, Customized(Participants) | BG00012 240 mg BID | BG00012 240 mg TID | Total |
|---|---|---|---|
| White | 285 | 309 | 594 |
| Black or African American | 10 | 16 | 26 |
| Asian | 82 | 80 | 162 |
| Other | 32 | 24 | 56 |
| Not Reported Due To Confidentiality Regulations | 459 | 439 | 898 |
Showing the first 100 of 246 sites across 34 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2009 to primary completion in Nov 2019, 129 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 129 months is above that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →